Waltham, MA, United States
Waltham, MA, United States

Time filter

Source Type

WALTHAM, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has entered into a relationship with the Pittsburgh Business Group on Health (PBGH) to offer the ILUSTRA Inflammation Management Program to PBGH employer-members in the Pittsburgh area as part of a company’s enhanced employee benefits plan. “PBGH is the region’s leading employer-led coalition designed to drive transparency in health care data, cost and quality. Western Pennsylvania has a history of health care innovation and we are delighted to be working together to build on this heritage,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “This relationship advances our commercial strategy by providing targeted access to many of the region’s most innovative employers. We have already contracted with one PGBH employer group and are advancing discussions with others.” According to Jessica Brooks, CEO & Executive Director, PBGH, the organization’s employer-members are interested in fostering this relationship in order to continue to drive better healthcare and wellness for their employees. “Our goal is to bring innovative programs to our employer-members to enable them to not only drive value in their benefits programs, but also to provide quality initiatives that impact wellness. We are committed to our members and will continue to assist in sharing best practices with other interested organizations,” she said. The ILUSTRA Inflammation Management Program targets individuals with elevated risk for severe periodontitis due to a genetic tendency to over-produce inflammation and directs them to obtain proper dental care. The program integrates three critical components: 1) a genetic risk test to identify patients at risk; 2) targeted education to healthcare professionals to individualize employee care plans; and 3) an 18-month subscription to the ILUSTRA Engagement Platform - a digital program that delivers engaging, personalized content tailored to maximize engagement and drive compliance and behavior change. Several studies link oral and systemic disease and document the significant impact of enhanced dental care to lower costs of medical management of certain chronic diseases like type 2 diabetes, cardiovascular disease and stroke. ILUSTRA is a proprietary program that has the potential to transform inflammation management by optimizing access to dental care to impact the onset and the progression of chronic diseases, and thereby reducing employer healthcare costs. About the ILUSTRA Inflammation Management Program The ILUSTRA Inflammation Management Program is designed to transform the management of inflammation. The program utilizes a genetic test to identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation. Such individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis. The program integrates educational outreach to the patient’s care team and provides reminders and content to patients to drive engagement. The ILUSTRA Inflammation Management Program is made available to employees in covered health plans under the supervision of a licensed dentist or physician. The ILUSTRA test is run solely in Interleukin’s CLIA-certified lab in suburban Boston. For more information, visit www.ILUSTRA.com. About PBGH Founded in 1981, the Pittsburgh Business Group on Health is a non-profit organization and business-only coalition representing more than 100 employer-member companies. PBGH promotes health care and benefits strategies through education, collaboration and innovation among members, and in the community, to deliver value and quality for members and their employees. About Interleukin Genetics, Inc. Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance. Interleukin Genetics’ lead products include its proprietary ILUSTRA Inflammation Management Program, an integrated program that utilizes a simple genetic test to easily identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation, and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com. Forward-Looking Statements Certain statements contained herein are “forward-looking” statements, including, but not limited to, statements that our ILUSTRA Inflammation Management Program has potential to provide significant health and economic value by improving the management of chronic inflammation and that certain individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in Interleukin’s annual report on Form 10-K for the year ended December 31, 2015, and other filings with the Securities and Exchange Commission. Interleukin disclaims any obligation or intention to update these forward-looking statements.


Patent
Interleukin Genetics and Access Business Group Intl. LLC | Date: 2015-11-25

This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subjects metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subjects metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subjects responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information.


Patent
Interleukin Genetics | Date: 2016-08-24

This application relates to methods and kits for detecting predisposition to increased risk for osteoarthritis associated conditions.


Patent
Interleukin Genetics and Tufts University | Date: 2010-07-09

Diagnostics and therapeutics for resistance to weight-loss, which are based upon the identification of a subjects PLIN polymorphisms, haplotype and genotype pattern, are described in this invention.


Patent
Interleukin Genetics and New York University | Date: 2016-08-10

This application relates to methods and kits for detecting predisposition to increased risk for osteoarthritis associated conditions.


Patent
Interleukin Genetics | Date: 2016-05-02

An improved method and kit of determining whether a patient is predisposed to having severe periodontal disease and/or having high risk of progression of periodontal disease, comprising the steps of (i) taking a biological sample from said patient; (ii) genotyping said biological sample for genetic polymorphism pattern comprising IL 1B (rs16944), IL 1B (rs1143623) and IL 1B (rs4848306); and (iii) comparing said genetic polymorphism patterns to a reference composite genotype pattern; wherein the similarity of said genetic polymorphism patterns to said reference pattern indicate said patients predisposition to having severe periodontal disease and/or having high risk of progression of periodontal disease.


An improved method and kit of determining whether a patient is predisposed to having severe periodontal disease and/or having high risk of progression of periodontal disease, comprising the steps of (i) taking a biological sample from said patient; (ii) genotyping said biological sample for genetic polymorphism pattern comprising IL 1B (rs16944), IL 1B (rs1143623) and IL 1B (rs4848306); and (iii) comparing said genetic polymorphism patterns to a reference composite genotype pattern; wherein the similarity of said genetic polymorphism patterns to said reference pattern indicate said patients predisposition to having severe periodontal disease and/or having high risk of progression of periodontal disease.


News Article | November 15, 2016
Site: globenewswire.com

WALTHAM, Mass., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial results for its fiscal third quarter of 2016, ended September 30, 2016, and provided a corporate update. “Interleukin Genetics continued to advance our commercial plan to drive market adoption of our Inflammation Management Program, which we recently relaunched as ILUSTRA™, that includes the genetic risk test (formerly known as PerioPredict®) that enables the identification and improved management of inflammation for individuals who may have a genetic predisposition to over-produce Interleukin-1 (IL-1), a key mediator of inflammation,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.  “During the third quarter, our focus was on integrating our expanded team to drive our commercial strategy and refining our strategies in deploying our field sales force, which we believe resulted in increased awareness of, and interest in, the ILUSTRA program.” “We are also excited about the demonstrated value of our IL-1 platform in cardiac disease.  The publication in The Lancet by our collaborator, Ionis Pharmaceuticals, reporting the utility of our technology in clinical studies of their drug candidate IONIS-APO(a)-LRX is further validation of the role of IL-1 genetics, and is consistent with impressive data we have generated in other collaborations. The strength and consistency of data on IL-1 in the cardiac area is very encouraging, and we are accelerating our efforts to drive value from these new applications of our platform.” Total revenue was $734,000 for the three months ended September 30, 2016 compared to $296,000 for the three months ended September 30, 2015. The change in total revenue is primarily attributable to contracted research projects recognized in Other revenue. Research and development expenses were $418,000 for the three months ended September 30, 2016, compared to $412,000 for the three months ended September 30, 2015. Selling, general and administrative expenses were $1.7 million for the three months ended September 30, 2016, compared to $1.4 million for the three months ended September 30, 2015.  The 19% increase is primarily attributable to recruiting fees and compensation related to new staff in sales and marketing and higher consulting costs partially offset by lower commissions related to our Merchant Network and Channel Partner Agreement with Amway Global and lower accounting fees. The Company reported a net loss of $1,966,505, or ($0.01) per diluted share for the three months ended September 30, 2016, compared to a net loss of $2,025,510, or ($0.01) per share in the comparable period in 2015. Total revenue was $2.3 million for the nine months ended September 30, 2016 compared to $1.1 million for the nine months ended September 30, 2015. The change in total revenue is largely attributable to contract research projects, partially offset by a decrease in kits returned for processing related to ABG’s promotional product bundle. Research and development expenses were $1.4 million for the nine months ended September 30, 2016, compared to $979,000 for the nine months ended September 30, 2015. The 38% increase of $371,000 is primarily attributable to expenses related to Dr. Ken Kornman moving back to the R&D department in April 2015 as President and Chief Scientific Officer from his previous position as CEO. While he served as CEO, expenses generated by Dr. Kornman were recorded as selling, general and administrative expenses. The increase in research and development expenses was also partially due to increased compensation expense related to annual salary increases for existing staff and our patient engagement study. Selling, general and administrative expenses were $4.7 million for the nine months ended September 30, 2016, compared to $4.6 million for the nine months ended September 30, 2015.  The 2% increase is primarily attributable to higher legal and consulting expenses partially offset by lower recruiting and patent fees as well as lower commissions related to our Merchant Network and Channel Partner Agreement with Amway Global.    The Company reported a net loss of $5,571,442, or ($0.03) per diluted share for the nine-month period ended September 30, 2016, compared to a net loss of $6,035,490, or ($0.03) per share in the nine-month period ended September 30, 2015. As of September 30, 2016, the Company had cash and cash equivalents of $4.3 million. On July 29, 2016, the Company completed a private placement transaction with various accredited investors, raising gross proceeds of approximately $5.6 million. The Company also restructured its existing debt with Horizon Technology Finance Corporation to revise the timing of the principal payments due under the loan. The Company expects that its current cash and cash equivalents will be sufficient to support the Company’s operations into the second quarter of 2017. The ILUSTRA Inflammation Management Program is designed to transform the management of inflammation. The program utilizes a genetic test to identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation. Such individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis. The program integrates educational outreach to the patient’s care team and provides reminders and content to patients to drive engagement. The ILUSTRA Inflammation Management Program is made available to employees in covered health plans under the supervision of a licensed dentist or physician. The ILUSTRA test is run solely in Interleukin’s CLIA-certified lab in suburban Boston. For more information, visit www.ILUSTRA.com. Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels. Interleukin Genetics’ lead products include its proprietary ILUSTRA™ Inflammation Management Program for periodontal disease and tooth loss susceptibility available through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA, and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com. Certain statements contained herein are “forward-looking” statements, including statements that cash and cash equivalents as of September 30, 2016, are sufficient to support operations into the second quarter of 2017, that individuals with genetic predisposition to over-produce IL-1 may benefit from enhanced dental care to prevent or treat periodontitis and thereby lower their systemic inflammatory burden, and that IL-1 genetic variations have the potential to inform clinical and commercial strategies for certain drugs for cardiac disease. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company’s annual report on Form 10-K for the year ended December 31, 2015, and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.


WALTHAM, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has entered into a partnership with the Greater Philadelphia Business Coalition on Health (GPBCH) to make the ILUSTRA Inflammation Management Program available to GPBCH employer-members in the Philadelphia area as part of a company’s enhanced employee benefits plan. The collaboration is designed to introduce ILUSTRA to coalition members and to assist employer members in implementing and evaluating the innovative ILUSTRA program. “We’re proud to be working with GPBCH to educate its members on the health benefits that may result from improved employee engagement through the ILUSTRA program,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “This relationship continues to advance our commercial strategy by providing preferred access to this region’s most innovative employers. We are delighted to have our first GPBCH member on board, and are advancing discussions to include other employers.” “The Greater Philadelphia Business Coalition on Health (GPBCH) is excited to foster this relationship in order to continue to drive better healthcare and wellness for our employer members and their employees. We believe this innovative program has the potential to significantly improve health and lower costs, and we have committed to assist in evaluating the program’s impact in order to share findings and best practices with other interested employers,” said Neil Goldfarb – President and CEO of GPBCH The ILUSTRA Inflammation Management Program targets individuals with elevated risk for severe periodontitis due to a genetic tendency to over-produce inflammation and directs them to obtain proper dental care. The program integrates three critical components: 1) a genetic risk test to identify patients at risk; 2) targeted education to healthcare professionals to individualize employee care plans; and 3) an 18-month subscription to the ILUSTRA Engagement Platform - a digital program that delivers engaging, personalized content tailored to maximize engagement and drive compliance and behavior change. Several studies link oral and systemic disease and document the significant impact of enhanced dental care to lower costs of medical management of certain chronic diseases like type 2 diabetes, cardiovascular disease and stroke. ILUSTRA is a proprietary program that has the potential to transform inflammation management by optimizing access to dental care to impact the onset and the progression of chronic diseases, and thereby reducing employer healthcare costs. About the ILUSTRA Inflammation Management Program The ILUSTRA Inflammation Management Program is designed to transform the management of inflammation. The program utilizes a genetic test to identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation. Such individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis. The program integrates educational outreach to the patient’s care team and provides reminders and content to patients to drive engagement. The ILUSTRA Inflammation Management Program is made available to employees in covered health plans under the supervision of a licensed dentist or physician. The ILUSTRA test is run solely in Interleukin’s CLIA-certified lab in suburban Boston. For more information, visit www.ILUSTRA.com. About Greater Philadelphia Business Coalition on Health (GPBCH) The Greater Philadelphia Business Coalition on Health (GPBCH) is an employer membership organization focused on improving employee health, and the quality, safety and value delivered by the healthcare system.  The Coalition’s 45 current employer members represent 1.5 million lives nationally.  More information is available at www.gpbch.org. About Interleukin Genetics, Inc. Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance, including pharmacogenomics information to guide development and use of therapeutics.  Interleukin Genetics’ lead products include its proprietary ILUSTRA Inflammation Management Program, an integrated program that utilizes a simple genetic test to easily identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation; its cardiovascular test to guide treatment of high risk patients; and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com. Forward-Looking Statements Certain statements contained herein are “forward-looking” statements, including, but not limited to, statements that our ILUSTRA Inflammation Management Program has potential to provide significant health and economic value by improving the management of chronic inflammation and that certain individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in Interleukin’s annual report on Form 10-K for the year ended December 31, 2015, and other filings with the Securities and Exchange Commission. Interleukin disclaims any obligation or intention to update these forward-looking statements.


WALTHAM, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has entered into a relationship with mPulse Mobile, a leader in mobile health engagement, to offer the ILUSTRA Inflammation Management Program to their employees as an enhancement to the company’s employee benefits plan. “This innovative program is a clear match with our company values and mission,” said Brian Chudleigh, Chief Financial Officer at mPulse Mobile. “Affecting behavioral change toward a healthy lifestyle is the key to realizing long-term health, wellness and reduced healthcare costs. I am impressed with the ILUSTRA program in how it utilizes both genetic insights to identify risk and engagement tactics to empower change.” The ILUSTRA Inflammation Management Program targets individuals with elevated risk for severe periodontitis due to a genetic tendency to over-produce inflammation and directs them to obtain proper dental care. The program integrates three critical components: 1) a genetic risk test to identify patients at risk; 2) targeted education to healthcare professionals to individualize employee care plans; and 3) an 18-month subscription to the ILUSTRA Engagement Platform — a digital program that delivers engaging, personalized content tailored to maximize engagement and drive compliance and behavior change. Several studies link oral and systemic disease and document the significant impact of enhanced dental care to lower costs of medical management of certain chronic diseases like type 2 diabetes, cardiovascular disease and stroke. ILUSTRA is a proprietary program that has the potential to transform inflammation management by optimizing access to dental care to impact the onset and the progression of chronic diseases, and thereby reducing employer healthcare costs. “mPulse Mobile epitomizes a company at the forefront of wellness innovation,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “I’m very proud of our growing relationship with such forward-thinking leaders and we believe that our association with mPulse Mobile will both provide significant value to their employees and advance our commercial agenda with ILUSTRA.” About the ILUSTRA Inflammation Management Program The ILUSTRA Inflammation Management Program is designed to transform the management of inflammation. The program utilizes a genetic test to identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation. Such individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis. The program integrates educational outreach to the patient’s care team and provides reminders and content to patients to drive engagement. The ILUSTRA Inflammation Management Program is made available to employees in covered health plans under the supervision of a licensed dentist or physician. The ILUSTRA test is run solely in Interleukin’s CLIA-certified lab in suburban Boston. For more information, visit www.ILUSTRA.com. About mPulse Mobile mPulse Mobile, a leader in mobile health engagement, drives improved health outcomes and business efficiencies by engaging individuals with meaningful and interactive dialog. mPulse Mobile combines technology, analytics and industry expertise that helps healthcare organizations activate their customers to adopt healthy behaviors. With over 8 years, a hundred million messages sent, and 50+ Health Plan, Provider, Pharma and Wellness customers, mPulse Mobile has the data, the experience and the technology to drive healthy behavior change. About Interleukin Genetics, Inc. Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance, including pharmacogenomics information to guide development and use of therapeutics.  Interleukin Genetics’ lead products include its proprietary ILUSTRA Inflammation Management Program, an integrated program that utilizes a simple genetic test to easily identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation; its cardiovascular test to guide treatment of high risk patients; and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com. Forward-Looking Statements Certain statements contained herein are “forward-looking” statements, including, but not limited to, statements that our ILUSTRA Inflammation Management Program has potential to provide significant health and economic value by improving the management of chronic inflammation; that certain individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis; and the benefits our relationship with mPulse Mobile will bring to mPulse Mobile and its employees and Interleukin. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in Interleukin’s annual report on Form 10-K for the year ended December 31, 2015, and other filings with the Securities and Exchange Commission. Interleukin disclaims any obligation or intention to update these forward-looking statements.

Loading Interleukin Genetics collaborators
Loading Interleukin Genetics collaborators